A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy in Patients With Inflammatory Knee Osteoarthritis (KOA)
Latest Information Update: 12 Jan 2026
At a glance
- Drugs PPV-06 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Peptinov
Most Recent Events
- 18 Dec 2025 According to a Peptinov Media Release, the company is planning phase 2 studies in 2026.
- 12 Aug 2025 Planned End Date changed from 1 Dec 2027 to 1 Dec 2028.
- 12 Aug 2025 Planned primary completion date changed from 1 Dec 2027 to 1 Dec 2028.